Komipharm International Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 1,184.85 million compared to KRW 1,780.73 million a year ago. Net loss was KRW 3,979.1 million compared to KRW 6,513.79 million a year ago.

Basic loss per share from continuing operations was KRW 57 compared to KRW 93 a year ago. Diluted loss per share from continuing operations was KRW 57 compared to KRW 93 a year ago. Basic loss per share was KRW 57 compared to KRW 93 a year ago.